{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:20:39Z","timestamp":1778599239066,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s40123-015-0038-y","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T08:30:10Z","timestamp":1439973010000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline"],"prefix":"10.1007","volume":"4","author":[{"given":"Laura A.","family":"Vickers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeya K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,20]]},"reference":[{"key":"38_CR1","doi-asserted-by":"crossref","unstructured":"Epidemiology Subcommittee DEWS Workshop. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):93\u2013107.","DOI":"10.1016\/S1542-0124(12)70082-4"},{"issue":"5\u20136","key":"38_CR2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3109\/08820538.2014.962663","volume":"29","author":"D Raoof","year":"2014","unstructured":"Raoof D, Pineda R. Dry eye after laser in situ keratomileusis. Semin Ophthalmol. 2014;29(5\u20136):358\u201362.","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"38_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archophthalmol.2008.608","volume":"127","author":"MM Brown","year":"2009","unstructured":"Brown MM, Brown GC, Brown HC, et al. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol. 2009;127(2):146\u201352.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"38_CR4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archinte.159.12.1359","volume":"159","author":"OD Schein","year":"1999","unstructured":"Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159(12):1359\u201363.","journal-title":"Arch Intern Med"},{"issue":"9","key":"38_CR5","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","volume":"118","author":"SE Moss","year":"2000","unstructured":"Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118(9):1264\u20138.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"38_CR6","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archopht.118.6.819","volume":"118","author":"B Munoz","year":"2000","unstructured":"Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000;118(6):819\u201325.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"38_CR7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","volume":"121","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475\u201383.","journal-title":"Ophthalmology"},{"issue":"2","key":"38_CR8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/jop.2012.0210","volume":"29","author":"S Yandrapu","year":"2013","unstructured":"Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther. 2013;29(2):236\u201348.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"38_CR9","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/eye.2012.68","volume":"26","author":"DM Paskowitz","year":"2012","unstructured":"Paskowitz DM, Nguyen QD, Gehlbach P, et al. Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study. Eye (Lond). 2012;26(7):944\u20139.","journal-title":"Eye (Lond)"},{"key":"38_CR10","unstructured":"http:\/\/www.prnewswire.com\/news-releases\/shire-reports-top-line-results-on-opus-2-a-phase-3-study-investigating-the-use-of-lifitegrast-50-ophthalmic-solution-in-adults-with-dry-eye-disease-234660341.html ."},{"key":"38_CR11","unstructured":"http:\/\/www.medscape.com\/viewarticle\/843968 ."},{"key":"38_CR12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.2147\/OPTH.S40798","volume":"8","author":"T Kashima","year":"2014","unstructured":"Kashima T, Itakura H, Akiyama H, Kishi S. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal. Clin Ophthalmol. 2014;8:1003\u201310.","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"38_CR13","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.ophtha.2012.06.052","volume":"119","author":"S Kinoshita","year":"2012","unstructured":"Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology. 2012;119(12):2471\u20138.","journal-title":"Ophthalmology"},{"issue":"9","key":"38_CR14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/ICO.0b013e318294f97e","volume":"32","author":"S Koh","year":"2013","unstructured":"Koh S, Inoue Y, Sugmimoto T, et al. Effect of rebamipide ophthalmic suspension on optical quality in the short break-up time type of dry eye. Cornea. 2013;32(9):1219\u201323.","journal-title":"Cornea"},{"issue":"8","key":"38_CR15","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/ICO.0000000000000456","volume":"34","author":"A Igarashi","year":"2015","unstructured":"Igarashi A, Kamiya K, Kobashi H, Shimizu K. Effect of rebamipide ophthalmic suspension on intraocular light scattering for dry eye after corneal refractive surgery. Cornea. 2015;34(8):895\u2013900.","journal-title":"Cornea"},{"issue":"6","key":"38_CR16","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ophtha.2012.12.022","volume":"120","author":"S Kinoshita","year":"2013","unstructured":"Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology. 2013;120(6):1158\u201365.","journal-title":"Ophthalmology"},{"issue":"3","key":"38_CR17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2011.0142","volume":"28","author":"Y Takeji","year":"2012","unstructured":"Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28(3):259\u201363.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"38_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/01.ico.0000126436.25751.fb","volume":"23","author":"H Urashima","year":"2004","unstructured":"Urashima H, Okamoto T, Takeji Y, et al. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo model. Cornea. 2004;23(6):613\u20139.","journal-title":"Cornea"},{"key":"38_CR19","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/OPTH.S44688","volume":"7","author":"K Meerovitch","year":"2013","unstructured":"Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275\u201385.","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"38_CR20","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.exer.2011.06.014","volume":"93","author":"P Jain","year":"2011","unstructured":"Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp Eye Res. 2011;93(4):503\u201312.","journal-title":"Exp Eye Res"},{"key":"38_CR21","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01960010 ."},{"key":"38_CR22","unstructured":"http:\/\/www.mimetogen.com\/clinical-development.html ."},{"key":"38_CR23","unstructured":"http:\/\/www.mimetogen.com\/news-publications\/press-releases\/51-mimetogen-pharmaceuticals-announces-topline-results-of-its-second-clinical-study-with-mim-d3-for-the-treatment-of-dry-eye-syndrome.html ."},{"key":"38_CR24","unstructured":"http:\/\/investors.ocutx.com\/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2032479 ."},{"key":"38_CR25","unstructured":"http:\/\/www.ocutx.com\/pipeline\/dexamethasone-punctum-plug ."},{"key":"38_CR26","unstructured":"http:\/\/investors.ocutx.com\/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2009132 ."},{"issue":"10","key":"38_CR27","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1073\/pnas.1217996110","volume":"110","author":"J Hou","year":"2013","unstructured":"Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci. 2013;110(10):3913\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"38_CR28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/ICL.0000000000000152","volume":"41","author":"MH Goldstein","year":"2015","unstructured":"Goldstein MH, Tubridy KL, Agahigian J, et al. A phase 2 exploratory study of a novel interleukin-1 receptor inhibitor (EBI-005) in the treatment of moderate-to-severe allergic conjunctivitis. Eye Contact Lens. 2015;41(3):145\u201355.","journal-title":"Eye Contact Lens"},{"issue":"8","key":"38_CR29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40265-015-0409-7","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Diquafosol ophthalmic solution 3%: a review of its use in dry eye. Drugs. 2015;75(8):911\u201322.","journal-title":"Drugs"},{"key":"38_CR30","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00831662 ."},{"issue":"10","key":"38_CR31","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","volume":"119","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto Y, Ohashi Y, Watanabe H, et al. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119(10):1954\u201360.","journal-title":"Ophthalmology"},{"issue":"10","key":"38_CR32","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","volume":"96","author":"E Takamura","year":"2012","unstructured":"Takamura E, Tsubota K, Watanabe H, et al. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96(10):1310\u20135.","journal-title":"Br J Ophthalmol"},{"key":"38_CR33","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01843894 ."},{"key":"38_CR34","unstructured":"http:\/\/www.businesswire.com\/news\/home\/20141109005056\/en\/R-Tech-Ueno-Completion-Phase-III-Clinical-Study-.VYOo6mAXN6k ."},{"key":"38_CR35","doi-asserted-by":"crossref","unstructured":"Schopf L, Enlow E, Popov A, et al. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol Ther. 2014. doi: 10.1007\/s40123-014-0021-z .","DOI":"10.1007\/s40123-014-0021-z"},{"key":"38_CR36","unstructured":"http:\/\/www.businesswire.com\/news\/home\/20150401005554\/en\/Kala-Pharmaceuticals-Announces-Positive-Results-Phase-2-.VYOvQWAXN6k ."},{"issue":"5","key":"38_CR37","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","volume":"104","author":"SK Lai","year":"2007","unstructured":"Lai SK, O\u2019Hanlon DE, Harrold S, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci. 2007;104(5):1482\u20137.","journal-title":"Proc Natl Acad Sci"},{"key":"38_CR38","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02313454 ."},{"issue":"2","key":"38_CR39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jconrel.2010.07.107","volume":"147","author":"S Gungor","year":"2010","unstructured":"Gungor S, Delgado-Charro MB, Ruiz-Perez B, et al. Trans-scleral iontophoretic delivery of low molecular weight therapeutics. J Control Release. 2010;147(2):225\u201331.","journal-title":"J Control Release"},{"key":"38_CR40","first-page":"633","volume":"5","author":"MA Patane","year":"2011","unstructured":"Patane MA, Cohen A, From S, et al. Ocular iontophoresis of EGP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol. 2011;5:633\u201343.","journal-title":"Clin Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-015-0038-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T17:54:11Z","timestamp":1498240451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40123-015-0038-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,20]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s40123-015-0038-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,20]]}}}